Efficacy, tolerability, and patient satisfaction with 50- and 100-mg sumatriptan tablets in those initially dissatisfied with the efficacy of 50-mg sumatriptan tablets

Clinical Therapeutics

Volumn 23, Issue 2, 2001, Pages 260-271

  Savani, Narendra ^a   Pfaffenrath, Volker ^b   Rice, Leanne ^c   Boswell, Diane ^c   Black, Libby ^d   Jones, Martin ^c   Scott, Andrew ^d  

^a Colne House Surgery ^*  (United Kingdom)

^b GlaxoSmithKline Research and Development ^*

^c GLAXOSMITHKLINE   (United Kingdom)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Efficacy; Migraine; Patient satisfaction; Sumatriptan

Indexed keywords

ANTIMIGRAINE AGENT; SEROTONIN AGONIST; SUMATRIPTAN;

ADULT; ANALGESIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; NAUSEA; PAIN ASSESSMENT; PATIENT SATISFACTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0035080784     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(01)80008-4     Document Type: Article

References (9)

1. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: Defining the optimum doses of oral sumatriptan
2. Oral sumatriptan for the acute treatment of migraine: Evaluation of three dosage strengths
3. Oral sumatriptan is effective and well tolerated for the acute treatment of migraine: Results of a multicenter study
4. Patient-selected dosing in a six-month, open-label study evaluating oral sumatriptan in the acute treatment of migraine
5. Patient preference for oral sumatriptan 25 mg, 50 mg, or 100 mg in the acute treatment of migraine: A double-blind, randomized, crossover study
6. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain
7. On the combination of independent two-sample tests of Wilcoxon